Novel cerebrospinal fluid biomarkers of axonal degeneration in frontotemporal dementia

  • Authors:
    • Niklas Mattsson
    • Ulla Rüetschi
    • Yolande A.L. Pijnenburg
    • Marinus A. Blankenstein
    • Vladimir N. Podust
    • Susann Li
    • Inger Fagerberg
    • Lars Rosengren
    • Kaj Blennow
    • Henrik Zetterberg
  • View Affiliations

  • Published online on: September 1, 2008     https://doi.org/10.3892/mmr_00000025
  • Pages: 757-761
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Frontotemporal dementia (FTD) is a heterogeneous disease with substantial interpersonal variance in aggressiveness. Novel biomarkers for rapidly progressive FTD could improve diagnosis and provide clues regarding its pathogenesis. In this study, surface-enhanced laser desorption/ionization time-of-flight (SELDI-TOF) mass spectrometry (MS) was used to analyze peptide profiles in cerebrospinal fluid (CSF) from 24 FTD patients. Thirteen patients had rapidly progressive FTD with distinct pathology in a brain MRI after less than 3 years of disease duration. Eleven patients had slowly progressive FTD with a normal brain MRI, but had abnormal findings in SPECT/PET after more than 5 years of disease duration. The axonal damage marker CSF neurofilament light-chain (NF-L) was measured in all subjects to evaluate the amount of axonal degeneration. A CSF NF-L level of 150 ng/l was used as a cut-off point for high NF-L expression. SELDI-TOF analysis of peptides in the range of 2000-20000 m/z revealed one peak with m/z of 6378 that was expressed at a significantly different level (p<0.01) when rapidly versus slowly progressive cases of FTD were compared. Eleven peaks were expressed at different levels when high versus low CSF NF-L were compared. Using chromatographic purification followed by tandem mass spectrometric analysis, five of these peaks were identified as follows: C-terminal fragment of neuroendocrine protein 7B2 (3512.84 Da), C-terminal fragment of osteopontin (7658.19 Da) as well as its mono- and diphosphorylated forms (7738.16 Da and 7818.13 Da, respectively) and pancreatic ribonuclease (14566.33 Da). The peak intensity of pancreatic ribonuclease was higher in patients with low NF-L expression, while the other peptides had a lower peak intensity in this group. Altered levels of these peptides have also been described in other neurodegenerative diseases. Taken together, these data suggest that differentially-expressed peptides are general markers of axonal degeneration. Further studies are needed to verify their prognostic value in FTD.

Related Articles

Journal Cover

September-October 2008
Volume 1 Issue 5

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Mattsson N, Rüetschi U, Pijnenburg YA, Blankenstein MA, Podust VN, Li S, Fagerberg I, Rosengren L, Blennow K, Zetterberg H, Zetterberg H, et al: Novel cerebrospinal fluid biomarkers of axonal degeneration in frontotemporal dementia. Mol Med Rep 1: 757-761, 2008.
APA
Mattsson, N., Rüetschi, U., Pijnenburg, Y.A., Blankenstein, M.A., Podust, V.N., Li, S. ... Zetterberg, H. (2008). Novel cerebrospinal fluid biomarkers of axonal degeneration in frontotemporal dementia. Molecular Medicine Reports, 1, 757-761. https://doi.org/10.3892/mmr_00000025
MLA
Mattsson, N., Rüetschi, U., Pijnenburg, Y. A., Blankenstein, M. A., Podust, V. N., Li, S., Fagerberg, I., Rosengren, L., Blennow, K., Zetterberg, H."Novel cerebrospinal fluid biomarkers of axonal degeneration in frontotemporal dementia". Molecular Medicine Reports 1.5 (2008): 757-761.
Chicago
Mattsson, N., Rüetschi, U., Pijnenburg, Y. A., Blankenstein, M. A., Podust, V. N., Li, S., Fagerberg, I., Rosengren, L., Blennow, K., Zetterberg, H."Novel cerebrospinal fluid biomarkers of axonal degeneration in frontotemporal dementia". Molecular Medicine Reports 1, no. 5 (2008): 757-761. https://doi.org/10.3892/mmr_00000025